Creative Medical Technology Holdings, Inc. disclosed on November 13, 2026, that it received a Nasdaq deficiency notice on November 10. The company failed to maintain the required $1.00 minimum closing bid price for 30 consecutive business days. The firm has until May 10, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
On November 10, 2026 the company received a Nasdaq deficiency notice because its closing bid price was below $1.00 for 30 consecutive business days. Delisting is not immediate: the company has a 180-day grace period until May 10, 2027 to regain compliance, plus a possible second 180-day period. The notice signals a sub-$1 stock price and dilution/reverse-split risk, but no near-term listing change.
- ▼ Nasdaq minimum bid price deficiency letter received November 10, 2026
- ▼ 180-day compliance deadline of May 10, 2027; must close at $1.00 or higher for ten consecutive business days
- ▲ Notice has no immediate impact on the Nasdaq listing
- ▲ Possible second 180-day grace period if all other initial listing standards are met